SHINE Technologies announced recently that it acquired Lantheus’ SPECT business, which includes the SPECT manufacturing facility in Massachusetts and its portfolio of diagnostic radiopharmaceuticals.

“The nuclear medicine supply chain needs to be modernized to keep up with patient needs,” SHINE Technologies Founder and CEO Greg Piefer said in a statement. “We’re building that now, bringing new technology to bear across both diagnostic and therapeutic markets. This strengthens the entire isotope supply ecosystem and positions SHINE to deliver the reliability healthcare depends on.”

According to a release, the acquisition integrates manufacturing expertise, customer relationships and established market position into SHINE’s nuclear medicine business.

The North Billerica, Mass., SPECT facility will now be called SHINE SPECT USA, LLC and led by CEO Michael Rossi. Among other products, it manufactures TechneLite, Cardiolite and NEUROLITE, which are used in millions of diagnostic imaging procedures annually for cardiac, pulmonary, thyroid, bladder and other applications.